GPR610: A Potential Drug Target and Biomarker (G59352)

Target Name: LGR6

NCBI ID: G59352

LGR6

GPR610: A Potential Drug Target and Biomarker

LGR6 (Leucine rich repeat containing G protein-coupled receptor 6, transcript variant 2) is a gene that encodes a protein known as GFR610. GFR610 is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and pancreas. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play an important role in cellular signaling.

GPR610 is a 14-kDa protein that is expressed in the brain, heart, and kidneys. It is highly expressed in the brain, with higher levels of expression in the prefrontal cortex compared to other regions of the brain. GPR610 is also expressed in the heart and kidneys, and has been shown to be involved in a variety of physiological processes, including cardiovascular function, neuroprotection, and homeostasis.

One of the unique features of GPR610 is its potential as a drug target. GPR610 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Its expression has also been associated with a number of diseases, including diabetes, hypertension, and heart failure. As a result, GPR610 has become a focus of interest for researchers studying the role of GPCR in disease.

In addition to its potential as a drug target, GPR610 has also been shown to be a potential biomarker. Its expression has been shown to be associated with a number of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. As a result, GPR610 has been used as a potential biomarker for a variety of diseases, including cancer and neurodegenerative diseases.

GPR610 is also of interest as a potential therapeutic target for a variety of diseases. Its expression has been shown to be associated with a number of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. As a result, GPR610 has been considered as a potential therapeutic target for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

In conclusion, LGR6 is a gene that encodes a protein known as GFR610, which is a member of the G protein-coupled receptor family. GPR610 is expressed in various tissues throughout the body and is involved in a variety of physiological processes. Its potential as a drug target and biomarker makes it an attractive target for research in disease. Furthermore, its potential therapeutic target makes it a promising target for the development of new treatments for a variety of diseases.

Protein Name: Leucine Rich Repeat Containing G Protein-coupled Receptor 6

Functions: Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a marker of multipotent stem cells in the epidermis. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, does not activate heterotrimeric G-proteins to transduce the signal. May act as a tumor suppressor

The "LGR6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGR6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets